DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme Jul 24, 2019
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting Jun 3, 2019
